All In Biotech

Drug Trial Radar · NCT02128113

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery

Last checked: Nov 19, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 307 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

307

Actual

Start

May 31, 2014

Primary completion

Feb 28, 2015

Study completion Apr 30, 2015

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
AbbVie
First posted
May 1, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408) ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract surgery.

Conditions

  • Corneal Endothelial Cell Loss
  • Ocular Pain
  • Ocular Inflammation
  • Cataract Surgery

Interventions

  • Vehicle Ophthalmic SolutionDrug

    Opthalmic suspension manufactured to mimic RTA 408 suspension

  • Omaveloxolone Ophthalmic Suspension 0.5%Drug

    0.5% ophthalmic suspension of RTA 408

  • Omaveloxolone Ophthalmic Suspension 1%Drug

    1% ophthalmic suspension of RTA 408

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Central Corneal Endothelial Cell CountsTime frame: 12 weeks

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Harvard Eye Associates

    Laguna Hills, California

  • Hull Eye Center

    Lancaster, California

  • Argus Research

    Cape Coral, Florida

  • Levenson Eye Associates

    Jacksonville, Florida

  • Chicago Cornea Consultants

    Hoffman Estates, Illinois

  • JacksonEye

    Lake Villa, Illinois

  • Discover Vision Centers

    Leawood, Kansas

  • Opthalmic Consultants of Boston

    Waltham, Massachusetts

  • Talamo Hatch Laser Eye Consultants

    Waltham, Massachusetts

  • Associated Eye Care

    Stillwater, Minnesota

  • Comprehensive Eye Care

    Washington, Missouri

  • Alterman, Modi and Wolter

    Poughkeepsie, New York

  • Cincinnati Eye Institute

    Cincinnati, Ohio

  • R & R Eye Research

    San Antonio, Texas

  • See Clearly Vision Group

    McLean, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.